"Site principal du Centre Hospitalier de Roubaix, l'hôpital Victor Provo de 585 lits fait l'objet de travaux d'optimisation et de modernisation réguliers depuis son ouverture en 1984 afin d'améliorer votre séjour. Il accueille les activités de médecine et de chirurgie. Ses équipements lourds se composent notamment de 3 scanners, 3 IRM, 2 gamma caméras, 1 TEP scan, un robot chirurgical, une unité de cardiologie interventionnelle et une unité d'angiographie interventionnelle..."

During the past decade, CH de Roubaix conducted 55 clinical trials. In the 10-year time frame, 55 clinical trials started and 1 clinical trials were completed, i.e. on average, 1.8% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CH de Roubaix" #1 sponsor was "University Hospital, Lille" with 24 trials, followed by "The Lymphoma Academic Research Organisation" with 9 trials sponsored, "Acute Leukemia French Association" with 6 trials sponsored, "Intergroupe Francophone de Cancerologie Thoracique" with 5 trials sponsored and "Lille Catholic University" with 5 trials sponsored. Other sponsors include 37 different institutions and companies that sponsored additional 39 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CH de Roubaix" #1 collaborator was "Ministry of Health, France" with 5 trials as a collaborator, "Assistance Publique - Hôpitaux de Paris" with 3 trials as a collaborator, "Région Nord-Pas de Calais, France" with 3 trials as a collaborator, "Acute Leukemia French Association" with 2 trials as a collaborator and "Groupe Francais De Pneumo-Cancerologie" with 2 trials as a collaborator. Other collaborators include 36 different institutions and companies that were collaborators in the rest 45 trials.

According to Clinical.Site data, the most researched conditions in "CH de Roubaix" are "Acute Myeloid Leukemia" (6 trials), "Critical Illness" (5 trials), "Acute Myeloid Leukemia (AML)" (2 trials), "Alzheimer's Disease" (2 trials) and "Carcinoma, Non-Small-Cell Lung" (2 trials). Many other conditions were trialed in "CH de Roubaix" in a lesser frequency.

Most popular intervention types in "CH de Roubaix" are "Drug" (37 trials), "Other" (19 trials), "Device" (10 trials), "Procedure" (7 trials) and "Biological" (6 trials). Other intervention types were less common.

The name of intervention was led by "Doxorubicin" (3 trials), "Placebo" (3 trials), "Rituximab" (3 trials), "Administration of the IPREA3 questionnaire" (2 trials) and "Bleomycin" (2 trials). Other intervention names were less common.

The vast majority of trials in "CH de Roubaix" are 86 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "CH de Roubaix". 2 are not yet recruiting, 16 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 50 completed trials in CH de Roubaix, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in CH de Roubaix, 2 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 29 trials that are defined as “Not Applicable".